[Radioimmunoassay of apolipoprotein A - I and A - II of human plasma high density lipoprotein and its clinical use]. 1983

T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001053 Apolipoproteins Protein components on the surface of LIPOPROTEINS. They form a layer surrounding the hydrophobic lipid core. There are several classes of apolipoproteins with each playing a different role in lipid transport and LIPID METABOLISM. These proteins are synthesized mainly in the LIVER and the INTESTINES. Apolipoprotein
D016632 Apolipoprotein A-I The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE. Apo A-I,Apo A-1,Apo A-I Isoproteins,Apo A1,Apo AI,ApoA-1,ApoA-I,Apolipoprotein A-1,Apolipoprotein A-I Isoprotein-2,Apolipoprotein A-I Isoprotein-4,Apolipoprotein A-I Isoproteins,Apolipoprotein A1,Apolipoprotein AI,Apolipoprotein AI Propeptide,Pro-Apo A-I,Pro-Apolipoprotein A-I,Proapolipoprotein AI,Apo A I Isoproteins,Apolipoprotein A 1,Apolipoprotein A I,Apolipoprotein A I Isoprotein 2,Apolipoprotein A I Isoprotein 4,Apolipoprotein A I Isoproteins,Pro Apo A I,Pro Apolipoprotein A I
D016633 Apolipoprotein A-II The second most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. It has a high lipid affinity and is known to displace APOLIPOPROTEIN A-I from HDL particles and generates a stable HDL complex. ApoA-II can modulate the activation of LECITHIN CHOLESTEROL ACYLTRANSFERASE in the presence of APOLIPOPROTEIN A-I, thus affecting HDL metabolism. Apo A-II,Apo A-2,Apo A-II Isoproteins,Apo A2,Apo AII,ApoA-2,ApoA-II,Apolipoprotein A-2,Apolipoprotein A-II Isoproteins,Apolipoprotein A2,Apolipoprotein AII,Pro-Apo A-II,Pro-Apolipoprotein A-II,Proapolipoprotein A-II,Apo A II Isoproteins,Apolipoprotein A 2,Apolipoprotein A II,Apolipoprotein A II Isoproteins,Pro Apo A II,Pro Apolipoprotein A II,Proapolipoprotein A II

Related Publications

T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
June 1976, Metabolism: clinical and experimental,
T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
January 1976, Journal of lipid research,
T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
September 1977, Journal of lipid research,
T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
June 1987, Journal of lipid research,
T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
July 1987, Biochimica et biophysica acta,
T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
August 1974, The Journal of clinical investigation,
T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
January 1976, Journal of lipid research,
T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
February 2010, Arteriosclerosis, thrombosis, and vascular biology,
T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
June 2007, Biochemistry,
T Nakanishi, and S Akazawa, and K Toyama, and S Miyake, and S Nagataki
April 1980, The Journal of biological chemistry,
Copied contents to your clipboard!